Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Xencor, Inc. Appoints A. Bruce Montgomery, M.D as Director
Mar 19 15
Effective as of March 18, 2015, the Board of Directors of Xencor, Inc. appointed A. Bruce Montgomery, M.D. as a director of the company.
Xencor, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:30 PM
Feb 26 15
Xencor, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: John J. Kuch, Principal Financial Officer, Principal Accounting Officer and Vice President of Finance.
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Feb 19 15
Xencor, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $1,350,000 compared to $3,703,000 a year ago. Revenues were $5,664,000 against $1,745,000 a year ago. Loss from operations was $1,350,000 against $3,710,000 a year ago.
For the year, the company reported net loss of $16,422,000 compared to $60,259,000 a year ago. Fully diluted net loss per share was $0.52 compared to $3.85 a year ago. Revenues were $9,520,000 against $10,172,000 a year ago. Loss from operations was $16,457,000 against $10,520,000 a year ago.